By Stephen Nakrosis

 

GSK PLC on Wednesday said the U.S. Food and Drug Administration has approved Benlysta to treat children with active lupus nephritis.

GSK said Benlysta, or belimumab, was approved to treat children age 5 to 17 with active lupus nephritis who are receiving standard therapy. The company said this is the first FDA-approved treatment for pediatric LN.

GSK also said "the approval extends the current indication in the U.S. to include both lupus and active LN for the intravenous formulation in the pediatric patient population."

The U.S. National Institutes of Health said lupus nephritis is a disease affecting the kidneys. In children who have lupus, eight out of 10 will have kidney disease, the NIH said.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

July 27, 2022 14:11 ET (18:11 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Gsk Charts.